Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances
Liver cancer is considered one of the deadliest diseases with one of the highest disease
burdens worldwide. Among the different types of liver cancer, hepatocellular carcinoma is …
burdens worldwide. Among the different types of liver cancer, hepatocellular carcinoma is …
Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2‐dependent silencing of SLC7A11
Z Fan, G Yang, W Zhang, Q Liu, G Liu… - Journal of cellular …, 2021 - Wiley Online Library
Residue hepatocellular carcinoma (HCC) cells enduring hypoxic environment triggered by
interventional embolization obtain more malignant potential with little clarified mechanism …
interventional embolization obtain more malignant potential with little clarified mechanism …
Recent advancements of nanomedicine towards antiangiogenic therapy in cancer
A Mukherjee, VS Madamsetty, MK Paul… - International Journal of …, 2020 - mdpi.com
Angiogenesis is a process of generation of de-novo blood vessels from already existing
vasculature. It has a crucial role in different physiological process including wound healing …
vasculature. It has a crucial role in different physiological process including wound healing …
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
The CXC chemokine receptor type 4 (CXCR4) receptor and its ligand, CXCL12, are
overexpressed in various cancers and mediate tumor progression and hypoxia-mediated …
overexpressed in various cancers and mediate tumor progression and hypoxia-mediated …
HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma
M Chen, G Shu, X Lv, X Xu, C Lu, E Qiao, S Fang… - Biomaterials, 2022 - Elsevier
Transcatheter arterial chemoembolization (TACE) is widely used for the treatment of
advanced hepatocellular carcinoma (HCC). However, the long-term hypoxic …
advanced hepatocellular carcinoma (HCC). However, the long-term hypoxic …
Autophagy-targeted calcium phosphate nanoparticles enable transarterial chemoembolization for enhanced cancer therapy
Transarterial chemoembolization (TACE) is commonly used for treating advanced
hepatocellular carcinoma (HCC). However, the instability of lipiodol-drug emulsion and the …
hepatocellular carcinoma (HCC). However, the instability of lipiodol-drug emulsion and the …
Recent Progress in Advanced Hydrogel‐Based Embolic Agents: From Rational Design Strategies to Improved Endovascular Embolization
X Li, MW Ullah, B Li, H Chen - Advanced Healthcare Materials, 2023 - Wiley Online Library
Transcatheter arterial embolization, a minimally invasive treatment to deliberately occlude
the blood vessels, has become a safe and effective procedure for the management of …
the blood vessels, has become a safe and effective procedure for the management of …
[HTML][HTML] Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
The rapid development and remarkable success of checkpoint inhibitors have provided
significant breakthroughs in cancer treatment, including hepatocellular carcinoma (HCC) …
significant breakthroughs in cancer treatment, including hepatocellular carcinoma (HCC) …
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
YJ Xiang, K Wang, HM Yu, XW Li… - Hepatology …, 2022 - Wiley Online Library
Aim Transarterial chemoembolization (TACE) combined with a PD‐1 inhibitor and TACE
combined with a PD‐1 inhibitor and lenvatinib have recently been reported as promising …
combined with a PD‐1 inhibitor and lenvatinib have recently been reported as promising …